is it the aim of the trial to have Vo2peak become a new SOC.
I imagine that there is a high threshold for KOLs and clinicians to adopt a new SOC. Is there a strategy in place of how to manage this or is this only relevant post approval? How much pull does FDA approval and Pharma interest have in SOC adoption?
my concern is that clinicians simply stick with LVEF and don’t adopt Vo2peak - thus rendering CPACS obsolete.
VO2Peak vs VO2Max, page-21
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |